Share

March 2019; 6 (2) ArticleOpen Access

MRI phenotypes in MS

Longitudinal changes and miRNA signatures

Christopher C. Hemond, Brian C. Healy, Shahamat Tauhid, Maria A. Mazzola, Francisco J. Quintana, Roopali Gandhi, Howard L. Weiner, Rohit Bakshi
First published February 15, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000530
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1328

Share

Article Information

vol. 6 no. 2 e530
DOI: 
https://doi.org/10.1212/NXI.0000000000000530
PubMed: 
30800720
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received July 31, 2018
  • Accepted in final form November 9, 2018
  • First Published February 15, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Christopher C. Hemond, MD,
    2. Brian C. Healy, PhD,
    3. Shahamat Tauhid, MD,
    4. Maria A. Mazzola, MD,
    5. Francisco J. Quintana, PhD,
    6. Roopali Gandhi, PhD,
    7. Howard L. Weiner, MD and
    8. Rohit Bakshi, MD, MA
  1. Christopher C. Hemond, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Clinical Research Fellowship in Multiple Sclerosis was sponsored by the American Academy of Neurology Institute, with funding provided in part by Sanofi-Genzyme

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Brian C. Healy, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Statistical Methods in Medical Research, editorial board, 2008-Present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Merck Serono, 2009-Present Genzyme, 2014-2015 Novartis, 2012-2015 Verily Sciences, 2015-Present

    Research Support, Government Entities:

    1. NIH, 5R01HL113272-02, Biostatistician, 2013-Present NIH, 1UH2TR000890-01, Biostatistician, 2013-Present NIH, 1UL1TR001102-07, Biostatistician, 2011-Present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Shahamat Tauhid, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Neuroimaging, Managing Editor, 2015-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Maria A. Mazzola, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Francisco J. Quintana, PhD,
    6. Scientific Advisory Boards:

    1. TEVA scientific advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 2012 Editorial Board Member Systems Biomedicine 2012 Editorial Board Member Inmunologia (Spain) 2013- Associate Editor Immunology (UK) 2013- Senior Editorial Board Member American Journal of Clinical and Experimental Immunology 2014- Advisory Board MemberSeminars in Immunopathology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Teva, Blueprint Medicines, AnTolRx

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. EMD-Serono 2. Sanofi 3. Novartis 4. Teva 5. ONO

    Research Support, Government Entities:

    1. (1) NIH, R00 AI075285-01A2, Role PI, 2010-2012, (2) NIH, R01 AI093903-01, Role PI, 2011?2016, (3) NIH, K99AI075285-01A2, Role PI, 2009-2010, (4) NIH, 1R01NS102807-01A1, role PI, 09/01/18 ? 08/31/23, (5) NIH, R01 ES025530-02, role PI, 06/01/16 ? 05/31/21, (6) NMSS, JF 2161-A-5, role PI, 07/01/14 ? 06/30/19, (7) American Cancer Soc., 126566-RSG-14-198-01-LIB, role PI, 01/01/15 ? 12/31/18, (8) NMSS, RR-1601-07385, role PI, 10/01/16 ? 09/30/19, (9) Israel Cancer Research Fund, 15-975-ICG, role PI, 09/01/16 ? 08/30/19, (10) NIH-NIAID, 1R01AI126880-01A1, role PI, 02/01/17 ? 01/31/22, (11) NIH-NIAID, 2R01HL095722-06A1, role PI, 09/01/15 ? 08/31/20, (12) NMSS, PA-1604-08459, role PI, 06/01/17 ? 05/31/21, (13) NMSS, PA-1604-08459, role PI, 06/01/17 ? 05/31/21, (14) King Abdulaziz City for Science & Technology, 117427, role PI, 06/01/17 ? 05/31/18, (15) NIH, 5R01DK108894-01, role Co-I, 02/01/17 ? 01/31/22,

    Research Support, Academic Entities:

    1. (1) Harvard Medical School, Diversity and Community Partnership Faculty Fellowship, Role PI, 2010-2012, (2) BADERC, Pilot and Feasibility Award (Quintana), Role PI, 2010-2012

    Research Support, Foundations and Societies:

    1. (1) NMSS, RG4111A1/1, Role PI, 2009-2012, (2) NMSS, RG4048A11, Role Research Associate, 2008-2011

    Stock/Stock Options/Board of Directors Compensation:

    1. AnTolRx

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Roopali Gandhi, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am employed by Sanofi Genzyme, Associate Medical Director, starting from September 2017

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Sanofi Genzyme

    Research Support, Government Entities:

    1. NIH, UH2/UH3 000890-01, Co-PI, 5 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Race to Erase MS Stock/Stock Options, Medical Equipment & Materials: Sanofi, 2018

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Howard L. Weiner, MD and
    8. Scientific Advisory Boards:

    1. served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis, Tilos Therapeutics, CBridge Capital, Genentech, Genzyme, vTv Therapeutics, MedDay Pharmaceuticals

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biodextris Biogen Novartis Serono Teva Sanofi Genzyme Tilos Therapeutics Tiziana Life Sciences vTv Therapeutics MedDay Pharmaceuticals Genentech CBridge Capital

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. EMD Serono Google Life Sciences

    Research Support, Government Entities:

    1. NIH UH3TR000890 - PI - 08/01/13 ? 07/31/18 R01 NS087226 - PI - 09/30/14 ? 07/31/19 R01 EY027921 - PI - 09/01/17 ? 08/31/20

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Rohit Bakshi, MD, MA
    9. Scientific Advisory Boards:

    1. Dr. Bakshi has received consulting fees for advisory boards from (1) Bayer, (2) Biogen, )3) Celgene, (4) EMD Serono, (5) Genentech, (6) Guerbet, (7) Sanofi-Genzyme, and (8) Shire.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Dr. Bakshi serves as Editor-in-Chief of the Journal of Neuroimaging

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Bakshi has received consulting fees for advisory boards from Bayer, Biogen, Celgene, EMD Serono, Genentech, Guerbet, Sanofi-Genzyme, and Shire.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Bakshi has received research support from (1) EMD Serono and (2) Sanofi-Genzyme. Stock/Stock Options, Medical Equipment & Materials: Dr. Bakshi's spouse holds stock in (1) Biogen, Inc. 2012-present.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neurology (C.C.H., B.C.H., S.T., M.A.M., F.J.Q., R.G., H.L.W, R.B.) and Department of Radiology (R.B.); Brigham and Women's Hospital (C.C.H., B.C.H., S.T., M.A.M., F.J.Q., R.G., H.L.W, R.B.); Laboratory for Neuroimaging Research (C.C.H., S.T., R.H.); Partners Multiple Sclerosis Center (C.C.H., B.C.H., S.T., M.A.M., F.J.Q., R.G., H.L.W, R.B.); Ann Romney Center for Neurologic Diseases (C.C.H., B.C.H., S.T., M.A.M., F.J.Q., R.G., H.L.W, R.B.); and Harvard Medical School (C.C.H., B.C.H., S.T., M.A.M., F.J.Q., R.G., H.L.W., R.B.), Boston, MA.
  1. Correspondence
    Dr. Bakshi rbakshi{at}post.harvard.edu
View Full Text

Article usage

Article usage: March 2019 to March 2023

AbstractFullPdfSource
Feb 201915117593Highwire
Mar 2019232497180Highwire
Apr 201917438185Highwire
May 20193313333Highwire
Jun 2019157831Highwire
Jul 201979719Highwire
Aug 2019814735Highwire
Sep 201995120Highwire
Oct 2019115715Highwire
Nov 2019158523Highwire
Dec 201966813Highwire
Jan 20203638Highwire
Feb 202066120Highwire
Mar 202026821Highwire
Apr 202026441Highwire
May 202087823Highwire
Jun 202055210Highwire
Jul 202035117Highwire
Aug 202035029Highwire
Sep 2020712235Highwire
Oct 202048215Highwire
Nov 202074729Highwire
Dec 202095825Highwire
Jan 202183620Highwire
Feb 202133931Highwire
Mar 2021134326Highwire
Apr 202132621Highwire
May 202184411Highwire
Jun 202154720Highwire
Jul 202173221Highwire
Aug 202164128Highwire
Sep 202143620Highwire
Oct 202163633Highwire
Nov 202111420Highwire
Dec 20214248Highwire
Jan 20221225Highwire
Feb 202213319Highwire
Mar 202213714Highwire
Apr 202232825Highwire
May 202244221Highwire
Jun 202262620Highwire
Jul 20222177Highwire
Aug 202273415Highwire
Sep 202233421Highwire
Oct 202265423Highwire
Nov 2022109628Highwire
Dec 202223317Highwire
Jan 202344416Highwire
Feb 202363618Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles